TESARO, Inc. to Post FY2017 Earnings of ($8.61) Per Share, Leerink Swann Forecasts (TSRO)
TESARO, Inc. (NASDAQ:TSRO) – Research analysts at Leerink Swann raised their FY2017 EPS estimates for shares of TESARO in a research note issued to investors on Wednesday. Leerink Swann analyst S. Fernandez now anticipates that the biopharmaceutical company will post earnings per share of ($8.61) for the year, up from their prior estimate of ($8.89). Leerink Swann has a “Outperform” rating on the stock. Leerink Swann also issued estimates for TESARO’s Q4 2017 earnings at ($2.79) EPS, FY2018 earnings at ($7.75) EPS, FY2019 earnings at ($5.22) EPS, FY2020 earnings at ($2.11) EPS and FY2021 earnings at $0.49 EPS.
Several other equities analysts also recently weighed in on TSRO. ValuEngine upgraded TESARO from a “sell” rating to a “hold” rating in a research report on Tuesday, August 1st. Morgan Stanley reiterated an “overweight” rating and set a $183.00 target price on shares of TESARO in a research report on Thursday, August 10th. Robert W. Baird reiterated a “neutral” rating and set a $140.00 target price (down from $155.00) on shares of TESARO in a research report on Thursday, August 10th. Evercore ISI initiated coverage on TESARO in a research report on Wednesday, August 16th. They set an “in-line” rating and a $121.00 target price on the stock. Finally, Credit Suisse Group set a $190.00 target price on TESARO and gave the stock a “buy” rating in a research report on Friday, August 18th. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. TESARO has an average rating of “Buy” and an average price target of $161.72.
TESARO (TSRO) traded down $2.10 during midday trading on Friday, reaching $85.90. The company had a trading volume of 449,793 shares, compared to its average volume of 1,031,102. TESARO has a 1 year low of $84.42 and a 1 year high of $192.94. The company has a current ratio of 4.73, a quick ratio of 4.35 and a debt-to-equity ratio of 0.34.
TESARO (NASDAQ:TSRO) last released its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.47) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.16) by $0.69. TESARO had a negative return on equity of 93.39% and a negative net margin of 251.22%. The firm had revenue of $142.77 million for the quarter, compared to the consensus estimate of $130.57 million. During the same period in the prior year, the business posted ($1.72) earnings per share. The firm’s revenue for the quarter was up 740.3% compared to the same quarter last year.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. BlackRock Inc. grew its stake in TESARO by 5.7% during the 2nd quarter. BlackRock Inc. now owns 3,605,247 shares of the biopharmaceutical company’s stock valued at $504,230,000 after purchasing an additional 195,590 shares in the last quarter. Vanguard Group Inc. grew its position in shares of TESARO by 2.1% in the 2nd quarter. Vanguard Group Inc. now owns 2,978,236 shares of the biopharmaceutical company’s stock worth $416,537,000 after acquiring an additional 62,104 shares in the last quarter. State Street Corp grew its position in shares of TESARO by 17.9% in the 2nd quarter. State Street Corp now owns 1,168,913 shares of the biopharmaceutical company’s stock worth $163,496,000 after acquiring an additional 177,057 shares in the last quarter. Janus Henderson Group PLC grew its position in shares of TESARO by 24.9% in the 3rd quarter. Janus Henderson Group PLC now owns 895,556 shares of the biopharmaceutical company’s stock worth $115,616,000 after acquiring an additional 178,406 shares in the last quarter. Finally, BB Biotech AG grew its position in shares of TESARO by 6.5% in the 2nd quarter. BB Biotech AG now owns 877,990 shares of the biopharmaceutical company’s stock worth $122,796,000 after acquiring an additional 53,408 shares in the last quarter.
In other TESARO news, Director James O. Armitage sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, September 18th. The stock was sold at an average price of $117.13, for a total transaction of $1,171,300.00. Following the completion of the sale, the director now owns 10,000 shares in the company, valued at approximately $1,171,300. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, SVP Martin H. Jr. Huber sold 592 shares of the firm’s stock in a transaction that occurred on Friday, September 22nd. The shares were sold at an average price of $118.60, for a total value of $70,211.20. Following the sale, the senior vice president now owns 6,943 shares of the company’s stock, valued at approximately $823,439.80. The disclosure for this sale can be found here. In the last quarter, insiders sold 35,692 shares of company stock valued at $4,628,976. Insiders own 40.50% of the company’s stock.
TESARO Company Profile
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Receive News & Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related companies with MarketBeat.com's FREE daily email newsletter.